相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Longitudinal Analysis Suggests Epstein--Barr as Cause of Multiple Sclerosis
[Anonymous]
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Kjetil Bjornevik et al.
SCIENCE (2022)
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
F. Schweitzer et al.
JOURNAL OF NEUROLOGY (2021)
Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years
Tomas Kalincik et al.
NEUROLOGY (2021)
Apparent changes in the epidemiology and severity of multiple sclerosis
Nils Koch-Henriksen et al.
NATURE REVIEWS NEUROLOGY (2021)
Diagnosis and Treatment of Multiple Sclerosis A Review
Marisa P. McGinley et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis
Tamara Perez-Jeldres et al.
DRUGS (2021)
Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial
Ludwig Kappos et al.
JAMA NEUROLOGY (2021)
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
Marisa P. McGinley et al.
LANCET (2021)
Clinical Correlation of Multiple Sclerosis Immunopathologic Subtypes
W. Oliver Tobin et al.
NEUROLOGY (2021)
Mechanistic underpinning of an inside-out concept for autoimmunity in multiple sclerosis
Bert A. 't Hart et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2021)
CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis
Mohammed S. M. Almuslehi et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2020)
Long-term drug treatment in multiple sclerosis: safety success and concerns
Dejan Jakimovski et al.
EXPERT OPINION ON DRUG SAFETY (2020)
Pre-clinical and Clinical Implications of Inside-Out vs. Outside-In Paradigms in Multiple Sclerosis Etiopathogenesis
Haley E. Titus et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2020)
Silent progression in disease activity-free relapsing multiple sclerosis
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2019)
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Dalia Rotstein et al.
NATURE REVIEWS NEUROLOGY (2019)
Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis
Daniel Ontaneda et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
Jeffrey A. Cohen et al.
LANCET NEUROLOGY (2019)
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
Giancarlo Comi et al.
LANCET NEUROLOGY (2019)
Head-to-head drug comparisons in multiple sclerosis Urgent action needed
Carmen Tur et al.
NEUROLOGY (2019)
Sphingosine 1-phosphate: Lipid signaling in pathology and therapy
Andreane Cartier et al.
SCIENCE (2019)
Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations
Brian Barry et al.
NEUROLOGY AND THERAPY (2019)
Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis
Luca Prosperini et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Evolution of clinical trials in multiple sclerosis
Yinan Zhang et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients
Elizabeth A. Mills et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients
Elizabeth A. Mills et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Tanuja Chitnis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
No evident disease activity: The use of combined assessments in the management of patients with multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Treatment decisions in multiple sclerosis - insights from real-world observational studies
Maria Trojano et al.
NATURE REVIEWS NEUROLOGY (2017)
No evident disease activity: The use of combined assessments in the management of patients with multiple sclerosis
Gavin Giovannoni et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Disease-modifying therapies and infectious risks in multiple sclerosis
Alexander Winkelmann et al.
NATURE REVIEWS NEUROLOGY (2016)
Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis
Adnan M. Subei et al.
CNS DRUGS (2015)
Multiple sclerosis-a quiet revolution
Richard M. Ransohoff et al.
NATURE REVIEWS NEUROLOGY (2015)
Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulations
Daniele D'Ambrosio et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2015)
Immunopathology of multiple sclerosis
Calliope A. Dendrou et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Disability in Multiple Sclerosis
Maria Pia Sormani et al.
ANNALS OF NEUROLOGY (2014)
Lysophospholipid receptor nomenclature review: IUPHAR Review 8
Yasuyuki Kihara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2014)
Multiple-Dose Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponesimod, an S1P1 Receptor Modulator: Favorable Impact of Dose Up-Titration
P. Brossard et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial
Tomas Olsson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY
Paul Browne et al.
NEUROLOGY (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Effects of Ethnicity and Sex on the Pharmacokinetics and Pharmacodynamics of the Selective Sphingosine-1-Phosphate Receptor 1 Modulator Ponesimod: A Clinical Study in Japanese and Caucasian Subjects
Maribel Reyes et al.
PHARMACOLOGY (2014)
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study
Patrick Brossard et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Gregory T. Kunkel et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Therapies for multiple sclerosis: translational achievements and outstanding needs
Aiden Haghikia et al.
TRENDS IN MOLECULAR MEDICINE (2013)
Cortical lesions in multiple sclerosis: inflammation versus neurodegeneration
Hans Lassmann
BRAIN (2012)
Will the real multiple sclerosis please stand up?
Peter K. Stys et al.
NATURE REVIEWS NEUROSCIENCE (2012)
Sphingosine-1-phosphate signaling and its role in disease
Michael Maceyka et al.
TRENDS IN CELL BIOLOGY (2012)
Development of small-molecule inhibitors of sphingosine-1-phosphate signaling
Yvette Edmonds et al.
PHARMACOLOGY & THERAPEUTICS (2011)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
分享论文
